Current Rating and Its Implications
MarketsMOJO’s Strong Sell rating on Hikal Ltd indicates a cautious stance for investors, signalling that the stock is expected to underperform relative to the broader market and its sector peers. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The Strong Sell grade suggests that the company currently faces significant challenges that could impact shareholder returns negatively in the near to medium term.
Quality Assessment
As of 05 January 2026, Hikal Ltd’s quality grade is assessed as below average. The company has demonstrated weak long-term fundamental strength, with a compounded annual growth rate (CAGR) in operating profits of -16.24% over the past five years. This negative growth trend highlights operational difficulties and an inability to expand profitability sustainably. Additionally, the average return on equity (ROE) stands at a modest 8.00%, indicating limited efficiency in generating profits from shareholders’ funds. The company’s capacity to service debt is also a concern, with a high Debt to EBITDA ratio of 2.51 times, reflecting elevated leverage and potential financial risk.
Valuation Perspective
Despite the challenges in quality and financial performance, Hikal Ltd’s valuation grade is currently attractive. This suggests that the stock price has adjusted downward in response to the company’s deteriorating fundamentals, potentially offering value for investors who are willing to accept higher risk. However, attractive valuation alone does not offset the risks posed by weak financial trends and operational issues, and investors should weigh this factor carefully within the broader context.
Register here to know the latest call on Hikal Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Financial Trend Analysis
The financial trend for Hikal Ltd is very negative as of 05 January 2026. The company reported a drastic fall in earnings per share (EPS), with a decline of -320.54% in the most recent quarter ending September 2025. This sharp contraction in profitability is further underscored by two consecutive quarters of negative results. The quarterly profit after tax (PAT) stood at a loss of ₹34.90 crores, a significant deterioration compared to the previous four-quarter average. Return on capital employed (ROCE) is also at a low 4.44%, reflecting poor utilisation of capital resources. Moreover, the operating profit to interest coverage ratio is critically low at 0.48 times, indicating that operating profits are insufficient to comfortably cover interest expenses, raising concerns about financial stability.
Technical Outlook
Technically, Hikal Ltd’s stock is mildly bearish. The share price has been under pressure, with a one-day decline of -1.03% and a one-month fall of -6.95%. Over the past six months, the stock has lost -34.62% of its value, and the year-to-date return is slightly negative at -0.59%. The one-year return is particularly weak at -43.30%, signalling sustained investor pessimism. This underperformance extends beyond the short term, as the stock has lagged the BSE500 index over the last three years, one year, and three months, confirming a persistent downtrend.
Stock Returns and Market Performance
As of 05 January 2026, Hikal Ltd’s stock returns paint a challenging picture for investors. The stock has delivered a negative return of -43.30% over the past year, significantly underperforming the broader market benchmarks. The six-month return of -34.62% and three-month return of -11.22% further highlight the downward momentum. These returns reflect the market’s reaction to the company’s deteriorating fundamentals and financial health, reinforcing the rationale behind the Strong Sell rating.
Sector and Market Context
Operating within the Pharmaceuticals & Biotechnology sector, Hikal Ltd faces intense competition and regulatory pressures that compound its internal challenges. While the sector overall has seen pockets of growth driven by innovation and demand for healthcare products, Hikal’s weak financial trend and operational inefficiencies have hindered its ability to capitalise on these opportunities. Investors should consider the company’s relative underperformance within this sector when evaluating its prospects.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
What This Rating Means for Investors
The Strong Sell rating on Hikal Ltd serves as a cautionary signal for investors. It suggests that the stock is expected to continue facing headwinds due to weak fundamentals, deteriorating financial health, and negative technical trends. Investors should be wary of potential further declines and consider the risks carefully before initiating or maintaining positions in this stock. The attractive valuation may tempt some value-oriented investors, but the underlying financial and operational challenges warrant a conservative approach.
Conclusion
In summary, Hikal Ltd’s current Strong Sell rating by MarketsMOJO reflects a comprehensive assessment of its below-average quality, attractive valuation, very negative financial trend, and mildly bearish technical outlook. The rating was last updated on 14 November 2025, but the detailed analysis and data presented here are current as of 05 January 2026. Investors should interpret this rating as a strong indication to exercise caution, given the company’s ongoing struggles with profitability, debt servicing, and stock price performance within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
